State of the Art Review: New Insights in T Cell Prolymphocytic LeukemiaToby A Eyre1, Angela Hamblin2 and Anna Schuh2*
- *Corresponding Author:
- Dr Anna Schuh
Consultant Haematologist and Senior Lecturer
Oxford NIHR BRC Molecular Diagnostic Centre
Oxford University Hospitals NHS Trust
John Radcliffe Site, Oxford OX3 9DU, UK
Tel: +44 (0)1865 572826
Fax: +44 (0)1865 857095
E-mail: [email protected]
Received date: April 08, 2014; Accepted date: May 28, 2014; Published date: June 02, 2014
Citation: Eyre TA, Hamblinand A, Schuh A (2014) State of the Art Review: New Insights in T Cell Prolymphocytic Leukemia. J Leuk 2:138. doi: 10.4172/2329-6917.1000138
Copyright: © 2014 Eyre TA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
T cell ProLymphocytic Leukemia (T-PLL) is a rare lymphoid malignancy and is typified by its aggressive presentation and chemo-resistance. Given its rarity, haemato-oncologists are likely to manage only a handful of cases across their career and therefore making the diagnosis is the initial challenge. This diagnosis is critical, as recent data suggests that choosing specific treatment options, such as alemtuzumab, is important in improving outcomes.